A Single-Center, Prospective, Non-randomized Study Investigating the Long-Term Efficacy and Success Rate of Intravesical Electromotive Administration of Botulinum Toxin Type A (BoNTA) (Dysport) in Myelomeningocele (MMC) Patients who had Urinary Incontinence due to Neuropathic Detrusor Overactivity (NDO)

Trial Profile

A Single-Center, Prospective, Non-randomized Study Investigating the Long-Term Efficacy and Success Rate of Intravesical Electromotive Administration of Botulinum Toxin Type A (BoNTA) (Dysport) in Myelomeningocele (MMC) Patients who had Urinary Incontinence due to Neuropathic Detrusor Overactivity (NDO)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2017 New trial record
    • 08 Dec 2017 Results published in the Urology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top